Company Overview

StrionAir, Inc. manufactures and markets a patented, breakthrough air-filtration technology that renders existing air-filtration solutions technically inferior and cost ineffective. Based on pioneering research performed by Lawrence Livermore National Lab and commercialized by StrionAir's founders over the past ten years, StrionAir has created the industry's first germicidal, high efficiency, low pressure air filtration system.

StrionAir's System provides a compelling ROI that enables facilities managers to reduce operating costs, protect building occupants from airborne pathogens and pollutants and provide a more comfortable, productive work environment. The technology delivers additional benefits to facility owners and managers concerned with proactively addressing today's most important and litigious indoor air quality challenges including: biological- and radiological-related terrorist threats, sick building syndrome and nosocomial (hospital-acquired) infections.

Mission

StrionAir's mission is to provide the most technically superior, cost-effective germicidal air-purification products. In accordance with this mission, StrionAir provides a substantial return on investment to customers in the form of immediate, sustained and significant cost savings while providing a safer and healthier indoor environment.